Inpatient complications in patients with giant cell arteritis: decreased mortality and increased risk of thromboembolism, delirium and adrenal insufficiency.
暂无分享,去创建一个
[1] P. Merkel,et al. Incidence and mortality rates of biopsy-proven giant cell arteritis in southern Sweden , 2014, Annals of the rheumatic diseases.
[2] E. Kimchi,et al. Delirium in elderly people – Authors'reply , 2014, The Lancet.
[3] C. Brymer,et al. Prognosis of delirium in hospitalized elderly: worse than we thought , 2014, International journal of geriatric psychiatry.
[4] J. Saczynski,et al. Delirium in elderly people , 2014, The Lancet.
[5] L. Trupin,et al. A168: Systemic Lupus Erythematosus In‐Hospital Mortality Risk Across Ages: A National Estimate , 2014 .
[6] M. Chung,et al. The impact of age on the epidemiology of atrial fibrillation hospitalizations. , 2014, The American journal of medicine.
[7] P. Merkel,et al. Risk for Cardiovascular Disease Early and Late After a Diagnosis of Giant-Cell Arteritis , 2014, Annals of Internal Medicine.
[8] V. Neuhaus,et al. Psychiatric Disorders and Major Spine Surgery: Epidemiology and Perioperative Outcomes , 2014, Spine.
[9] G. Gondran,et al. Recovery of Adrenal Function after Long-Term Glucocorticoid Therapy for Giant Cell Arteritis: A Cohort Study , 2013, PloS one.
[10] C. Whitney,et al. U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination. , 2013, The New England journal of medicine.
[11] J. Springer,et al. Thrombosis in vasculitis , 2013, Current opinion in rheumatology.
[12] S. Gabriel,et al. Large-vessel involvement in giant cell arteritis: a population-based cohort study of the incidence-trends and prognosis , 2012, Annals of the rheumatic diseases.
[13] J. Kopec,et al. Risk of pulmonary embolism and deep vein thrombosis in systemic lupus erythematosus: a population-based cohort study , 2012, Arthritis Research & Therapy.
[14] A. Coleman,et al. Risk of fractures following cataract surgery in Medicare beneficiaries. , 2012, JAMA.
[15] K. Kraemer,et al. Perioperative all-cause mortality and cardiovascular events in patients with rheumatoid arthritis: comparison with unaffected controls and persons with diabetes mellitus. , 2012, Arthritis and rheumatism.
[16] Gordon H Guyatt,et al. Executive Summary Antithrombotic Therapy and Prevention of Thrombosis , 9 th ed : American College of Chest Physicians Evidence-Based Clinical Practice Guidelines , 2012 .
[17] J. Sundquist,et al. Risk of pulmonary embolism in patients with autoimmune disorders: a nationwide follow-up study from Sweden , 2012, The Lancet.
[18] C. Hill,et al. Mortality in Patients with Biopsy-proven Giant Cell Arteritis: A South Australian Population-based Study , 2011, The Journal of Rheumatology.
[19] Sreeram V Ramagopalan,et al. Risk of venous thromboembolism in people admitted to hospital with selected immune-mediated diseases: record-linkage study , 2011, BMC medicine.
[20] H. Erdem,et al. Investigation of the veins in patients with Behçet’s disease with no known vascular event by Doppler ultrasonography , 2012, Rheumatology International.
[21] K. Barraclough,et al. BSR and BHPR guidelines for the management of giant cell arteritis. , 2010, Rheumatology.
[22] Liang‐Kung Chen,et al. Ischemic stroke in the elderly: an overview of evidence , 2010, Nature Reviews Neurology.
[23] H. B. Fung,et al. Community-acquired pneumonia in the elderly. , 2010, The American journal of geriatric pharmacotherapy.
[24] S. Bornstein. Predisposing factors for adrenal insufficiency. , 2009, The New England journal of medicine.
[25] L. Calabrese,et al. Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases. , 2009, Arthritis and rheumatism.
[26] Marcelo Coca-Perraillon,et al. Incidence and mortality of hip fractures in the United States. , 2009, JAMA.
[27] K. Digre,et al. Giant cell arteritis and mortality. , 2009, The journals of gerontology. Series A, Biological sciences and medical sciences.
[28] R. Seror,et al. High frequency of venous thromboembolic events in Churg–Strauss syndrome, Wegener’s granulomatosis and microscopic polyangiitis but not polyarteritis nodosa: a systematic retrospective study on 1130 patients , 2008, Annals of the rheumatic diseases.
[29] P. Marik,et al. Requirement of perioperative stress doses of corticosteroids: a systematic review of the literature. , 2008, Archives of surgery.
[30] G. Hunder,et al. Polymyalgia rheumatica and giant-cell arteritis , 2008, The Lancet.
[31] E. Chakravarty,et al. Hospitalizations and mortality in systemic sclerosis: results from the Nationwide Inpatient Sample. , 2007, Rheumatology.
[32] G. Rubenfeld,et al. Trends in the use of the pulmonary artery catheter in the United States, 1993-2004. , 2007, JAMA.
[33] M. Naylor,et al. Acute coronary care in the elderly, part I: Non-ST-segment-elevation acute coronary syndromes: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology. , 2007, Circulation.
[34] J. Wakim,et al. Anesthetic implications for patients receiving exogenous corticosteroids. , 2006, AANA journal.
[35] P. Merkel,et al. Brief Communication: High Incidence of Venous Thrombotic Events among Patients with Wegener Granulomatosis: The Wegener's Clinical Occurrence of Thrombosis (WeCLOT) Study , 2005, Annals of Internal Medicine.
[36] S. Gabriel,et al. Reappraisal of the epidemiology of giant cell arteritis in Olmsted County, Minnesota, over a fifty-year period. , 2004, Arthritis and rheumatism.
[37] S. Gabriel,et al. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. , 2003, Arthritis and rheumatism.
[38] M. Cooper,et al. Corticosteroid insufficiency in acutely ill patients. , 2003, The New England journal of medicine.
[39] L. Nyström,et al. Increased mortality due to cardiovascular disease in patients with giant cell arteritis in northern Sweden. , 2002, The Journal of rheumatology.
[40] K. Wood,et al. Corticosteroid supplementation for adrenal insufficiency. , 2002, JAMA.
[41] T. Wilsgaard,et al. Survival in polymyalgia rheumatica and temporal arteritis: a study of 398 cases and matched population controls. , 2001, Rheumatology.
[42] D. Ibañez,et al. Giant cell arteritis in Lugo, Spain, is associated with low longterm mortality. , 1997, The Journal of rheumatology.
[43] G. Hunder,et al. Long-term survival of patients with giant cell arteritis in the American College of Rheumatology giant cell arteritis classification criteria cohort. , 1996, The American journal of medicine.
[44] R. Ratner,et al. Recovery of the hypothalamic-pituitary-adrenal (HPA) axis in patients with rheumatic diseases receiving low-dose prednisone. , 1993, The American journal of medicine.
[45] D A Bloch,et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. , 2010, Arthritis and rheumatism.
[46] V. James,et al. Recovery of hypothalamo-pituitary-adrenal function after corticosteroid therapy. , 1967, Lancet.